Amgen paying Arrowhead for traits to develop cardiovascular drugs

By Staff Report  /  Thursday, September 29th, 2016  /  Central Coast Health Watch, Latest news  /  Comments Off on Amgen paying Arrowhead for traits to develop cardiovascular drugs

Amgen will license two traits from a Pasadena pharmaceutical company to develop cardiovascular drugs under a partnership announced Sept. 29. Under the agreement, Thousand Oaks-based Amgen will pay Arrowhead Pharmaceuticals $35 million up front, $21.5 million in the form of an equity investment by Amgen in Arrowhead common stock, and up to $617 million in Read More →